Literature DB >> 31288634

Demonstrating the value of the oncology pharmacist within the healthcare team.

Eve M Segal1, Jill Bates2, Sara L Fleszar3, Lisa M Holle4,5, Julie Kennerly-Shah6, Michelle Rockey7, Kate D Jeffers8.   

Abstract

INTRODUCTION: Although many oncology pharmacists are embedded members within the healthcare team, data documenting their contributions to optimal patient outcomes are growing. The purpose of this paper is to demonstrate the value of the oncology pharmacist within the healthcare team and describe the knowledge, skills, and functions of the oncology pharmacist.
METHODS: A systematic literature review of articles that were published on PubMed between January 1951 and October 2018 was completed. Identified abstracts were reviewed and included if they focused on measuring the value or impact of the oncology pharmacist on provider/patient satisfaction, improvement of medication safety, improvement of quality/clinical care outcomes, economics, and intervention acceptance. Review articles, meta-analysis, and studies not evaluating oncology pharmacist activities were excluded. Studies were thematically coded into four themes (clinical care, patient education, informatics, and cost savings) by 10 oncology pharmacists.
RESULTS: Four-hundred twenty-two articles were identified, in which 66 articles met inclusion criteria for this review. The selected literature included 27 interventional and 38 descriptive studies. The value of the oncology pharmacist was demonstrated by published articles in four key themes: clinical care, patient education, informatics, and cost savings.
CONCLUSION: With an expected shortage of oncology physicians and the ongoing development of complex oncology therapies, the board-certified oncology pharmacist is well suited to serve as a physician extender alongside nurse practitioners and/or physician assistants as the medication expert on the oncology care team. The demonstrated value of the oncology pharmacist supports their role as frontline providers of patient care.

Entities:  

Keywords:  Cost savings; patient care team; patient satisfaction; pharmacists; value

Year:  2019        PMID: 31288634     DOI: 10.1177/1078155219859424

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  6 in total

1.  Beyond the Classroom: An Observational Study to Assess Student Pharmacists' Confidence and Perception of a High-Fidelity Manikin Chemotherapy Infusion Reaction Simulation.

Authors:  Jeremiah K Jessee; Akera Miller; Alex M Ebied
Journal:  J Pharm Technol       Date:  2022-01-26

Review 2.  Availability and role of clinical pharmacists in ambulatory neuro-oncology.

Authors:  Mallika P Patel; Eric S Lipp; Elizabeth S Miller; Patrick N Healy; James E Herndon; Katherine B Peters
Journal:  Neurooncol Pract       Date:  2021-10-22

3.  Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective.

Authors:  María Belen Marzal-Alfaro; Vicente Escudero-Vilaplana; Jose Luis Revuelta-Herrero; Roberto Collado-Borrell; Ana Herranz-Alonso; Maria Sanjurjo-Saez
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

4.  The Expanding Role of the Oncology Pharmacist.

Authors:  Lisa M Holle; Eve M Segal; Kate D Jeffers
Journal:  Pharmacy (Basel)       Date:  2020-07-25

5.  Interdisciplinary Cooperation between Pharmacists and Nurses-Experiences and Expectations.

Authors:  Magdalena Waszyk-Nowaczyk; Weronika Guzenda; Paweł Dragun; Laura Olsztyńska; Julia Liwarska; Michał Michalak; Jan Ferlak; Mariola Drozd; Renata Sobiechowska
Journal:  Int J Environ Res Public Health       Date:  2022-09-16       Impact factor: 4.614

6.  Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study.

Authors:  Jeremie Zerbit; Sylvie Chevret; Sophie Bernard; Marie Kroemer; Charlotte Ablard; Stephanie Harel; Pauline Brice; Isabelle Madelaine; Catherine Thieblemont
Journal:  Ann Hematol       Date:  2020-06-01       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.